AU4608096A - Production and administration of high titer recombinant retroviruses - Google Patents

Production and administration of high titer recombinant retroviruses

Info

Publication number
AU4608096A
AU4608096A AU46080/96A AU4608096A AU4608096A AU 4608096 A AU4608096 A AU 4608096A AU 46080/96 A AU46080/96 A AU 46080/96A AU 4608096 A AU4608096 A AU 4608096A AU 4608096 A AU4608096 A AU 4608096A
Authority
AU
Australia
Prior art keywords
administration
production
high titer
recombinant retroviruses
titer recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU46080/96A
Inventor
John R Allen
Jack R. Barber
Mordechai Bodner
Stephen M.W. Chang
Kimberly Chong
Dan De La Vega Jr.
Nicholas J Depolo
David Chi-Tang Hsu
Carlos E Ibanez
Douglas J. Jolly
Denice M Mittelstaedt
Charles E Prussak
James G. Respess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Viagene Inc filed Critical Chiron Viagene Inc
Publication of AU4608096A publication Critical patent/AU4608096A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU46080/96A 1994-12-30 1995-12-22 Production and administration of high titer recombinant retroviruses Abandoned AU4608096A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36707194A 1994-12-30 1994-12-30
US367071 1994-12-30
PCT/US1995/016852 WO1996021014A2 (en) 1994-12-30 1995-12-22 Production and administration of high titer recombinant retroviruses

Publications (1)

Publication Number Publication Date
AU4608096A true AU4608096A (en) 1996-07-24

Family

ID=23445824

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46080/96A Abandoned AU4608096A (en) 1994-12-30 1995-12-22 Production and administration of high titer recombinant retroviruses

Country Status (3)

Country Link
EP (1) EP0796331A2 (en)
AU (1) AU4608096A (en)
WO (1) WO1996021014A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
EP0915975A2 (en) * 1996-07-03 1999-05-19 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia
WO1999007870A1 (en) * 1997-08-11 1999-02-18 Chiron Corporation Methods for genetically modifying t cells
EP1009444A2 (en) * 1997-09-02 2000-06-21 Chiron Corporation Compositions and methods for treating arthritis utilizing gene therapy
JP2003286198A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Therapeutic medicine using protein hollow nanoparticle expression growth factor, and the like
JP2003286199A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Therapeutic medicine for hepatic disease using protein hollow nanoparticle
US6790641B2 (en) 2002-05-01 2004-09-14 Cell Genesys, Inc. Lentiviral vector particles resistant to complement inactivation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors

Also Published As

Publication number Publication date
WO1996021014A3 (en) 1996-09-26
WO1996021014A2 (en) 1996-07-11
EP0796331A2 (en) 1997-09-24

Similar Documents

Publication Publication Date Title
AU6833994A (en) Incorporation of taxol into liposomes and gels
AU6391394A (en) Medical devices and methods of manufacture
IL112860A0 (en) Recombinant viruses their preparation and their therapeutic uses
AU1913792A (en) Novel derivatives of thiopyranopyrrole and preparation thereof
AU2157192A (en) 4-aminoquinolines and pharmaceutical compositions thereof
AU7236596A (en) Transdermal administration of ropinirole and analogs thereof
AU7305594A (en) Physiologically active substance-prolonged releasing-type pharmaceutical preparation
AU5136093A (en) Peptide antagonists of sh2 binding and therapeutic uses thereof
AU4209589A (en) Combined jug and sprayer
AU4840293A (en) Cloning and expression of pur protein
AU3280297A (en) Nasal administration of desmopressin
AU4463996A (en) Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
AU6428890A (en) Therapeutic peptides and proteins
AU6856094A (en) Oxadiazole derivative and medicinal composition thereof
AU2749395A (en) Medical use of bromelain
AU3720193A (en) Hydroisoindolines and hydroisoquinolines as psychotropic drugs
AU1192892A (en) Pharmaceutical preparation of antistress, stress-preventive and nootropic action
AU1567588A (en) A pharmaceutical combination for the prophylaxis and therapy of malaria
AU4305897A (en) Pharmaceutical compositions containing amisulpride and therapeutic applications thereof
AU4608096A (en) Production and administration of high titer recombinant retroviruses
IL117078A0 (en) Substituted benzenesulfonylureas and -thioureas processes for their preparation their use for the production of pharmaceutical preparations and pharmaceutical preparations containing them
AU3734793A (en) Mutant gpibalpha fragments and recombinant expression thereof
AU5358894A (en) Recombinant alliinase, its preparation and pharmaceutical compositions comprising it
AU2512495A (en) Therapeutic phenoxyalkylazoles and phenoxyalkylazines
AU3439393A (en) Medical grade adhesives and their preparation